Title: The impact of open IP platforms on IP-strategy norms in life sciences
Authors: Tobias Thornblad; Thomas Hedner
Innovation and Entrepreneurship, The Sahlgrenska Academy, University of Gothenburg, PO Box 417, Gothenburg 405 30, Sweden.
Innovation and Entrepreneurship, The Sahlgrenska Academy, University of Gothenburg, PO Box 417, Gothenburg 405 30, Sweden
Abstract: In the biomedical field multiple stakeholders may collaboratively develop, package and build transactions around technology. This is often referred to as open innovation, open biotechnology or open source R&D. Intellectual Property (IP) and IP rights play important roles in collaborative platforms but little research has previously assessed the impact that such platforms exert on corporate IP-strategies. A case study was therefore conducted of the Innovative Medicines Initiative (IMI), CAMBIA Biological Open Source (BiOS) and the Medicines for Malaria Venture (MMV). Our results impact managerial decision-makers at pharmaceutical, biotech and agriscience companies intending to implement corporate open innovation and IP strategies.
Keywords: intellectual property strategy; open IP platforms; open innovation; open biotechnology; open source R&D; life sciences; multiple stakeholders; research and development; biomedical; pharmaceutical companies; biotech companies; agriscience companies.
Int. J. of Technology Intelligence and Planning, 2012 Vol.8, No.1, pp.60 - 74
Available online: 17 Jun 2012